IAG Team are Presenting at ASCO, American Society of Clinical Oncology
Meet IA’s team at the American Society of Clinical Oncology (ASCO) annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The group’s CEO, Dr. Olga Kubassova and Head of R&D, Dr. Diana Roettger will be attending the meeting to present and discuss the Company’s work in oncology and immuno-oncology. In particular, the use of advanced imaging and associated biomarkers in early phase and prove of concept studies as an exploratory methdology applie din addition to the state of the art RECIST measurements to reveal more precise information about the lesion size and perfusion.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com